WO2003033529A2 - Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies - Google Patents

Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies Download PDF

Info

Publication number
WO2003033529A2
WO2003033529A2 PCT/EP2002/011484 EP0211484W WO03033529A2 WO 2003033529 A2 WO2003033529 A2 WO 2003033529A2 EP 0211484 W EP0211484 W EP 0211484W WO 03033529 A2 WO03033529 A2 WO 03033529A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
leukemia
activators
inhibitors
associated molecules
Prior art date
Application number
PCT/EP2002/011484
Other languages
German (de)
English (en)
Other versions
WO2003033529A3 (fr
Inventor
Martin Zenke
Petr Bartunek
Jaime Madruga
Nicolas P. Koritschoner
Original Assignee
Max-Delbrück-Centrum für Molekulare Medizin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max-Delbrück-Centrum für Molekulare Medizin filed Critical Max-Delbrück-Centrum für Molekulare Medizin
Priority to AU2002362891A priority Critical patent/AU2002362891A1/en
Publication of WO2003033529A2 publication Critical patent/WO2003033529A2/fr
Publication of WO2003033529A3 publication Critical patent/WO2003033529A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • TR4 activators Use of TR4, TR4 activators, TR4 inhibitors or TR4-associated molecules for the treatment of leukaemic diseases
  • the invention relates to the use of TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules, such as e.g. Antibodies or ligands, and an agent comprising TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules for the diagnosis and treatment of tumor diseases and blood disorders, in particular leukemic diseases.
  • Fields of application of the invention are the pharmaceutical industry and medicine.
  • Nuclear receptors are key regulators of cell proliferation, cell differentiation and the various development processes of the cell. In many cases these receptors perform their function by binding to known ligands such as retinoids, steroids, thyroid hormone, eicosanoids and vitamin D. Furthermore, there is an even greater number of nuclear receptors that have no ligands or whose ligands have not yet been identified. These nuclear receptors are also called orphan
  • TR4 is an orphan receptor that is closely related to the TR2 receptor. Both receptors define a subfamily within the steroid / thyroid receptor family (Hirose et al., Mol. Endocriol., 8 (1994) 1667-1680).
  • a typical disease of blood-forming cells can be leukemia, for example.
  • the so-called leukemia cells can, for example, colonize in the bone marrow, usually also in the blood and in lymphatic tissues, but also in all other organs of the organism and lead there to further pathological processes.
  • Various methods are described in the prior art for diagnosing or treating tumor diseases which relate in particular to blood-forming cells. However, the methods and pharmaceutical agents currently available do not permit efficient and reliable diagnosis or therapy of the tumor diseases mentioned.
  • the object of the invention was therefore to provide methods and means with which tumor diseases, in particular those which relate to the hematopoietic system, can be diagnosed or treated prophylactically, treated and / or treated at an early stage.
  • the invention solves this technical problem by using TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules for diagnosis, prophylaxis, follow-up, therapy and / or post-treatment of tumor diseases and / or blood disorders.
  • TR4 means an orphan receptor. Accordingly, TR4-associated molecules are, in particular, ligands, antibodies or else markers that bind to the receptor. However, the person skilled in the art is aware that for certain examinations of the orphan receptor, he can use not only the receptor itself, but also the nucleic acid encoding the receptor. For the purposes of the invention, TR4 is therefore understood to mean the receptor both on the nucleic acid and on the amino acid level. TR4 can therefore be the receptor that naturally occurs on or in the cells, but also the nucleic acid that codes for this receptor. Of course, the TR4 receptor can also be synthetically produced receptors or their fragments.
  • the receptor can also be modified biological structures, such as a labeled structure such as HA-TR4 or a modified form such as a TR4 with a mutated DNA binding domain such as ⁇ TR4.
  • Nucleic acids encoding TR4 are all nucleic acids that code for a structure that is analogous to the receptor and has its biological function.
  • TR4-associated molecules can accordingly be any biological or chemical structure that can interact with TR4 in such a way that an interaction can be detected, such as RXR or modified forms such as ⁇ RXR. If the coding nucleic acid is used instead of the orphan receptor TR4, for the purposes of the invention, TR4-associated molecules are, for example, promoters or regulatory elements which stimulate or inhibit the expression of the orphan receptor TR4.
  • TR4-associated molecules can therefore also be understood as antisense constructs, in particular RNA interference molecules, which suppress the expression of the TR4 orphan receptor.
  • TR4 inhibitors or TR4 activators are all molecules that inhibit or activate the action of the TR4 at the nucleic acid or amino acid level.
  • RIP-140 is a co-activator that interacts with TR4 and can modulate its activity.
  • the skilled worker is familiar with further molecules which can be used as a TR4 activator or TR4 inhibitor.
  • the invention thus relates to the surprising teaching that TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules on the protein or nucleic acid level in diagnosis, prophylaxis, monitoring, therapy and / or in the aftertreatment of tumor diseases and / or blood disorders can be used.
  • Tumor diseases in the sense of the invention are all pathological changes in cells or cell collections, cell aggregates or tissues which lead to individual cells or cell groups not showing normal growth or differentiation behavior. This means that the cells can multiply uncontrollably, for example; it is also possible that blood stem cells no longer differentiate into mature blood cells, but remain in the stage of the transition from a blood stem cell to a differentiated cell and do not develop into a mature cell.
  • Blood disorders in the sense of the invention can be any deviations from the normal physiological value that affect individual blood cells or blood precursor cells, such as hemolytic disease, hemophilia, bleeding abnormalities and certain forms of leukemia, unless they are associated with the tumor diseases.
  • Blood disorders are accordingly all pathological changes in the erythrocytes or erythrocyte precursor cells Granolocytes, monocytes, lymphocytes and platelets as well as all progenitor cells of these cells as well as all pathological changes in plasma proteins or other components of the serum.
  • the orphan receptor TR4 is surprisingly strongly expressed in hematopoietic cells and tissues and exerts a strong influence on these cells. Accordingly, by detecting the orphan receptor at the protein or nucleic acid level, in particular the DNA or RNA level, it can be diagnosed by comparison with control values of healthy patients whether individual blood or blood precursor cells are in a physiological or pathophysiological Condition.
  • the control or standard values can relate to the concentration or activity of the receptor, the number of nucleic acids encoding it, the concentration or activity or ligands or other parameters.
  • TR4-associated molecules other than the ligand also allows diagnostic conclusions to be drawn about the condition of individual cells or the tissues which have the receptor and / or its coding nucleic acids. If the person skilled in the art has detected a pathological level of TR4 or TR4-associated molecules, he is able, particularly by genetic engineering or pharmacological interventions, to modify the activity or the concentration of TR4 or TR4-associated molecules in such a way that a physiological or normal or largely healthy condition can be achieved. Such methods are known to the person skilled in the art.
  • TR4 supports or induces the proliferation of myeloid progenitor cells; if the person skilled in the art wishes to prevent the proliferation of these cells, in particular in a patient or else in a culture medium, he can selectively use inhibitors or antagonists of the TR4 at the protein or DNA or RNA level to prevent them. If, on the other hand, the person skilled in the art wants to induce the proliferation of myeloid precursor cells in an organism or in a cell culture, he can use, for example, activators which increase the activity of the orphan receptor TR4 or its expression. Such substances are known to the person skilled in the art.
  • TR4 comprises a TR4 receptor with a deleted DNA binding domain.
  • this structure is also referred to as ⁇ TR4.
  • the orphan receptor which has a deleted DNA binding domain, is advantageously present not only in the cell nucleus, but also in the cytoplasm of TR4-transformed cells, in particular fibroblasts and myeloid cells.
  • TR4 can advantageously be used in the suppression and activation of transcription factors involved in gene expression. This double activity of TR4 is particularly dependent on the TR4 DNA contacts or on TR4 cofactor bonds, it is of course also possible that the activity is dependent on both contacts or bonds.
  • TR4 with a deleted DNA binding domain does not attach to certain TR4 binding sites, such as AGGTCAAAGGTCA.
  • TR4 with the deleted DNA binding domain - ⁇ TR4 - suppresses the transcriptional activation that depends on RXR or the thyroid hormone receptor-dependent transcriptional activation.
  • ⁇ TR4 can be used in processes or uses in which the suppression of transcription or binding to the DNA is not desired. is.
  • ⁇ TR4 allows myeloid cells to grow.
  • TR4 and ⁇ TR4 are advantageously expression identical. This means that the growth-promoting activity of TR4 is also present in ⁇ TR4, with ⁇ TR4 advantageously not suppressing transcription or not binding DNA.
  • TR4-associated molecules are either ligands, RXR and / or RIP-140.
  • Various ligands in particular small, low molecular weight molecules, are known to the person skilled in the art and can be used to specifically bind to the receptor TR4.
  • TR4-associated molecules can, however, also preferably be RXR and / or RIP-140.
  • TR4 has a strong repressive effect on RXR-mediated transcription.
  • RXR it is also possible to use an RXR structure which no longer has a DNA-binding domain or whose DNA-binding domain has been deleted.
  • RIP-140 is a co-activator that interacts with TR4 and can advantageously be used for diagnosis, prophylaxis, follow-up, therapy and / or post-treatment of tumor diseases and / or blood disorders.
  • the therapy and / or after-treatment of the tumor disease and / or the diseases of the blood is a differentiation therapy.
  • non-toxic pharmaceutical compositions can be used to induce or promote a terminal differentiation of, in particular, leukemic cells.
  • Such substances can be, for example, PMA, retinoids, vitamin D, vitamin E, vitamin A, beta-carotene, estrogens, glucocorticoids, interferons, TNF, dimethyl sulfoxides, N-methylformamides and PKC activators or inhibitors. All of these substances can be used together with TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules. be used to treat tumor diseases and / or blood disorders.
  • TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules are used to produce a medicament for the treatment of tumor diseases and / or blood disorders.
  • the medicament can in particular comprise at least one pharmaceutically acceptable carrier.
  • leukemia is diagnosed and treated as a tumor disease.
  • Preleukemia, acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, chronic myeloid leukemia, secondary leukemia and / or chronic lymphatic leukemia are preferably diagnosed and / or treated as leukemia.
  • Leukemia in the sense of the invention is a collective term for diseases that result from malignant transformation of hematopoietic and / or lymphatic cells, with proliferation and accumulation of neoplastic cells - the so-called leukemia cells - primarily taking place in the bone marrow, but mostly also in the blood and in lymphatic tissues and in other organs.
  • Acute leukemia or ' immature cell leukosis is a disease of the hematopoietic stem cells with proliferation immature Blasts in the bone marrow and mostly also in the blood.
  • Acute lymphoblastic leukemia or acute lymphoblastic leukemia is the most common childhood leukemia, the pathogenesis of which is characterized by a malignant transformation of a lymphatically determined stem cell.
  • acute lymphoblastic leukemia is also understood to mean lymphoblastic non-Hodgkin's disease.
  • Acute myeloid leukemia or acute non-lymphatic leukemia in the sense of the invention is leukemia which affects approximately 80% of all acute leukemia in adulthood and is the second most common childhood leukemia. This disease is induced by the malignant transformation of a myeloidally determined stem cell.
  • Acute undifferentiated leukemia is a rarely diagnosed form to which most leukemias can be assigned in the sense of the invention.
  • Chronic lymphoblastic leukemia is a common chronic leukemia that has a low degree of malignancy and is characterized by enlargement of the spleen and liver.
  • Chronic myeloid leukemia is middle-aged leukemia, whereby in the sense of the invention the acquired Philadelphia chromosome is detectable in most cases.
  • Chronic myelomonocytic leukemia is a stem cell disease belonging to the myelodysplastic syndromes. Smoldering leukemia is the slow course of acute - mostly myeloid - leukemia, which can be demonstrated by a low DNA-metabolism in the bone marrow cells.
  • secondary leukemia is a term which is not used uniformly, since secondary leukemia can arise as a result of other hematopoietic stem cell diseases, in particular myelodysplasias. Accordingly, all forms of leukemia due to toxic influences are secondary leukemia in the sense of the invention.
  • TR4 activators, TR4 inhibitors and / or TR4-associated molecules Treatment of the above-mentioned leukemias, intrathecal chemotherapy, adequate supportive measures such as blood cell replacement, infection prophylaxis and treatment are also used. Treatment with cytostatics or a bone marrow transplant is also possible.
  • the patients in question can also be treated by a splenectomy, optionally with gamma globulins, anthrax irradiation, administration of cytostatics and interferons and similar therapy schemes known to the person skilled in the art.
  • the invention also relates to the use of TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules for the proliferation and / or differentiation of blood cells, pluripotent and / or determined stem cells.
  • TR4, ⁇ TR4, or TR4 activators, inhibitors and / or TR4-associated molecules can be used for the proliferation, differentiation and / or outgrowth of various cells, in particular blood cells and blood precursor cells.
  • TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules are used to proliferate blood cells or pluripotent and / or determined stem cells or to induce outgrowth of these cells.
  • TR4; TR4 activators, TR4 inhibitors and / or TR4-associated molecules are used to prevent terminal differentiation of blood cells, hematopoietic cells, pluripotent and / or determined stem cells.
  • the invention also relates to the use of TR4, TR4 activators and / or TR4-associated molecules for the production of myeloid progenitor cells.
  • Myeloid progenitor cells are all cells that can develop into megakaryocytes, thrombocytes, eosinophils, neutrophils, basophils, mast cells, macrophages, monocytes and antigen-presenting cells.
  • the invention also relates to the use of TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules for the screening of medicaments.
  • the methods of multiple peptide synthesis, nanosynthesis reactions or free and polymer-bound polymer libraries or low-molecular libraries can be used. It is also possible to use the phage display method, combinatorial mutagenesis or in vitro protein synthesis to analyze libraries in order to detect structures that interact with TR4 or TR4-associated molecules as a potential drug. Basic work on generating libraries is also known to the person skilled in the art, such as, for example, pin synthesis, the process of dividing-mixing, dividing-coupling-reuniting, the synthesis of one peptide per grain, the parallel-chemical synthesis and / or spot synthesis. The identified product can then be Synthesis such as microsequencing or mass spectrometry, affinity selection, chemical coding or otherwise determined.
  • the invention also relates to the use of TR4 and / or TR4-associated molecules for identifying or isolating a TR4 antagonist or activator or agonist, the potential activator or antagonist being brought into contact with the TR4 and / or TR4-associated molecules and the binding, activation or inhibition of the TR4 or the TR4-associated molecules is determined.
  • TR4 has been detected as an orphan receptor on or in hematopoietic cells according to the invention, it is possible for a person skilled in the art to determine which ligands or antagonists or activators can bind to TR4 and a physiological one with the aid of association, interaction or binding tests or induce pathophysiological signal chain.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising TR4, TR4 activators, TR4 inhibitors and / or TR4-associated molecules, optionally with a pharmaceutically acceptable carrier.
  • the activity of the TR4 receptor can be influenced with the composition.
  • the invention also relates to a diagnostic kit comprising TR4, TR4 activators, TR4 inhibitors and / or TR-associated molecules.
  • Chicken marrow cells from 3 to 10 day old SPAFAS chickens were prepared and the cells cultured.
  • the bone marrow cells were grown for 2 to 4 hours in standard nutrient medium consisting of DMEM, 8% fetal calf serum, 2% chicken serum, 20 mM HEPES (pH 7.3) and 100 units penicillin / streptomycin, standard nutrient medium.
  • the non-adherent cells were then processed and used for infection and the infected cells in DMEM, 8% FCS, 5% chicken serum, 0.128 mg / ml chicken transferrin (conalbumin), 100 ng / ml recombinant chicken stem cell factor, 20 mM HEPES (pH 7.3) and 100 units penicillin / streptomycin were cultivated at a cell density of 2 to 3 x 10 6 cells / ml.
  • the chicken embryo fibroblasts were grown in the standard growth medium.
  • the virus-producing chicken embryo fibroblasts were prepared and the bone marrow cells were infected using standard methods.
  • the infections were carried out in the presence of 1 ⁇ g / ml recombinant human insulin and 100 ng / ml stem cell factor.
  • a retroviral vector was constructed which contained the entire strand length of the TR4-CDNA down along the CMV promoter. Wild-type Human-TR4 was installed at the EcoRI interface of pSFCV-LE. The TR4 versions labeled with haagglutinin were first converted to a carrier vector which contained coding sequences for three hemagglutinin epitopes upwards along the clone sites. In the HA- ⁇ TR4 amino acid, positions 64 to 232, which encompass the entire DNA binding domain of human TR4, were removed. Then the EcoRV-EcoRI- Locations of pSFCV-LE HA-TR4 and HA- ⁇ TR4 installed. Recombinant retroviral vectors, the RXR and - ⁇ RXR freed from its DNA binding domain are already state of the art.
  • RNA production, cDNA synthesis and PCR amplification are carried out according to the standard procedures.
  • a total of 20 to 50 ⁇ l of strand cDNA was first synthesized from 2-5 ⁇ g of total RNA using 100 U M-MLV revertase and random hexamer primers.
  • a set of degenerate primers was developed for the area encoding the DNA binding domain of the nuclear receptors. These primers had the following sequences:
  • NHR4 5 '-TGYAARNNNTTYTTYMRNMG-3'.
  • the strand cDNA was first subjected to 40 cycles of PCR amplification using Taq DNA polymerase and with the following cycle profile: 30 seconds at 94 ° C., 90 seconds at 37 ° C. and 20 seconds at 72 ° C.
  • the following primer combinations were used: In the first reaction, NHR1 or NHR2 together with NHR3.
  • the product of this reaction was diluted 1: 300 and used as a matrix for the reaction with NHR3 and NHR4.
  • the PCR products were purified by gel electrophoresis and incorporated into the vector pCRII.
  • the resulting clones were sequenced and then the sequences were analyzed using the BLAST tool to identify functional units.
  • the Genbank accession number for the Chicken TR4 is AF133054.
  • the following primary cells were used: human cells: erythroid rogenitors, peripheral blood T cells and monocytes; Mouse cells: dendritic cells; Chicken cells: SCF and STED erythroblasts. 15 ⁇ g RNA were analyzed by Northern blot. For this purpose, the filters were hybridized with 32 P-labeled human or chicken TR4-specific probes, washed moderately intensively and photographed.
  • Cells were collected for flow cytometry, washed with PBS (1% BSA) and incubated with primary antibodies (1 h). The following monoclonal antibodies were used: MC47-83, MC51-2, MC22-3; Kl, 2G11; JS8 and JS4, CD3, CD4 and CD8; MEP17, MEP21, MEP26 and EOS47; DM-GRASP (BEN1); HEM-CAM antibody; CD44 (AV6). The cells were then incubated with FITC-conjugated anti-mouse IgG for one hour, washed and slurried in PBS (1% BSA, 2 ⁇ g / ml propidium iodide) in order to allow the viable cells to emerge. These cells were analyzed using flow cytometry.
  • the entire cell extracts were prepared on a 10 percent SDS-PAGE gel and blotted on nitrocellulose membranes.
  • the following antibodies were used: anti-hemagglutinin 12CA5, anti-CEBPß, anti-Mim-I.
  • the blots were then washed and incubated with the corresponding secondary antibody for 45 minutes in PBS (5% non-fat milk powder) at room temperature, developed and photographed.
  • the chicken embryo fibroblasts containing the TR4 versions were cultured as above and trypsin was added. They were then given the opportunity to adhere to glass slides (1 h, 37 ° C). The cells were washed and fixed with PBS (3.7% paraformaldehyde) for 15 minutes. After fixation, the cells were made permeable with PBS (0.5% NP-40) (15 min), incubated with 0.5% thermally inactivated FCS in PBS for 30 minutes to block possible non-specific bindings, and Reacted with anti-hemagglutinin 12CA5 for 1 h, followed by reaction with FITC-conjugated anti-mouse IgG (1 h). In addition, the samples were stained with TRITC-labeled phalloidin for actin.
  • DAPI (0.5 mg / ml) was used to stain the cell nuclei.
  • the samples were washed with PBS and fixed in Mowiol 4.88 containing 50 mg / ml DABCO as a bleach protection agent. All incubations were carried out at room temperature.
  • Trypsin peptide maps were created using the reversed phase HPLC ( ⁇ RPC C2 / C18 SC 2nd 1/10 column). The flow rate was 100 ⁇ l / min at 25 ° C using a linear acetonitrile gradient in 0.1% trifluoroacetic acid.
  • the peptides of interest were placed on a glass filter fiber of a procise- coated with Biobrene Sequenators applied. The subsequent sequencing was carried out using standard protocols.
  • the chicken embryo fibroblasts were dissolved in a buffer solution of 20 mM Tris pH 7.5, 2 mM DTT, 20% glycerol and 400 mM KCl - (1 h on ice).
  • the complete cell extracts (5 - 10 ⁇ g) were incubated for 15 minutes on ice with a 32 P-labeled oligonucleotide which is the DRI-HRE binding site
  • the chicken embryo fibroblasts were transiently transfected with retroviral expression vectors which contained TR4, HA-TR4 and HA- ⁇ TR4, in combination with eukaryotic expression vectors which carried RXR in pSG5, and a luciferase reporter with rat CRBPII-RXRE.
  • retroviral expression vectors which contained TR4, HA-TR4 and HA- ⁇ TR4, in combination with eukaryotic expression vectors which carried RXR in pSG5, and a luciferase reporter with rat CRBPII-RXRE.
  • RSV-ß-galactose and pCHHO plasmids were also cotransfected.
  • the transfected cells were grown in a standard nutrient medium which largely contained FCS and chicken serum extracted from retinoids. 9cRA (10 "6 M) was added.
  • the cell extracts were prepared and for their luciferase and ⁇ -galactosidase activity analyzed.
  • the luciferase values were normalized to investigate the ⁇ -galactosidase activity.
  • TR4 is surprisingly strongly expressed in hematopoietic cells and tissues and exerts a strong influence on these cells. Furthermore, it was found that TR4 ectopically expressed in the bone marrow by means of a retrovirus vector promotes the proliferation of myeloid progenitor cells. Another finding is that the activity of TR4 does not depend solely on its association with DNA, because the expression of a mutated version of TR4 without the possibility of DNA binding leads to the same proliferative potential as with wild-type TR4.
  • orphan receptor TR4 is an important regulator of the proliferation and development of myeloid progenitor cells.
  • TR4 was found in human myeloid cell lines (U937, HL60) and primary monocytes and dendritic cells (Fig. 1A). TR4 was similarly pronounced in rat myeloid cells (Fig. 1B). Moderate was found in the T cells and only a little TR4 in the B cells. In addition, TR4 was immediately detectable in human, mouse and chicken erythroid cell lines (K562, E31 and HD3) and in the primary progenitors of red blood cells (Figs. 1A, B and C). As expected, there was a high level of TR4 expression in the brain. The TR4 level was also high in the thymus and somewhat lower in bursa and spleen (Fig. IC). Accordingly, TR4 transcripts were found in chicken B, T and dendritic cells. As a result, TR4 is present in a number of different cell types in the haematopoietic system.
  • TR4 effectively induces the proliferation of myeloid progenitor cells.
  • TR4 was ectopically expressed in chicken bone marrow cells and the effects of the receptor on the proliferation or development of these cells were investigated.
  • a retroviral vector carrying TR4-CDNA was constructed and transfected into the chicken embryo fibroblasts and the neomycin-resistant cells were selected. The cells clearly showed the TR4 protein. (Fig. 3) and were used as a source for infection of the bone marrow cells with the virus.
  • TR4 caused a cell outgrowth within 4 to 5 days, which could not be found in the reference cultures infected with an empty vector (Fig. 2).
  • the cells grew in large aggregates consisting of several hundreds of cells (Fig. 2). This proliferation stopped after 14 to 16 days.
  • Fig. 2 Histological examination of the TR4 cells showed a similarity to myeloid progenitors (Fig. 2).
  • the cells had an average diameter of 9 ⁇ and were further characterized by flow cytometry using a panel of monoclonal antibodies with regard to the appearance of cell surface markers (Fig. 2).
  • a high expression of the myeloid markers MC47-83, MC51-2 and MC22-3 and MHC class II was found in the TR4 cells.
  • Kl a macrophage marker
  • JS8 a transferrin receptor was found as expected (since the cells were in the exponential growth phase).
  • the TR4 cells had neither the T cell-specific marker (CD3, CD4 and CD8) nor the erythroid-specific marker (JS4) or the eosinophilic marker (EOS47; Fig. 2).
  • HEM-CAM an adhesion molecule from earlier hematopoietic progenitors
  • CD44 another adhesion molecule in the form of different hematopoietic cell types
  • MEP17 / ⁇ 2 / ßl integrin was found in the TR4 cells, while MEP21 / thrombomucin, which occurs to a large extent on platelets and multipotent myeloid progenitors, platelet and erythroid cells, was missing. It can be concluded that TR4 cells are arky myeloid progenitors due to their morphological properties and the profile of their cell surfaces.
  • TR4 The growth-promoting activity of TR4 is impaired, but not eliminated, when its DNA binding domain is deleted.
  • TR4 has been described as a transcription factor involved in the suppression and activation of gene expression. This double activity can depend significantly on the TR4 DNA contacts or TR4 cofactor (s) linkages, or both.
  • TR4 cofactor (s) linkages or both.
  • Fig.3B the subcellular localization of the TR4 proteins was determined by indirect immunofluorescence (Fig. 3).
  • HA-TR4 was clearly restricted to the cell nucleus, while the HA- ⁇ TR4 protein appeared both in the cell nucleus and in the cytoplasm.
  • TR4 and its closest "relative" TR2 share a highly homologous nuclear localization signal in their DNA binding domain and it is precisely this motif that was removed in HA- ⁇ TR4.
  • the staining of chicken embryo fibroblasts containing empty vectors with hemagglutinin-specific antibodies was negative.
  • HA-TR4 had effectively attached to the TR4 binding site contained in DR1-HRE (AGGTCAAAGGTCA), whereas HA- ⁇ TR4 had not (Fig. 4).
  • the band corresponding to HA-TR4 was shifted slightly more than with the unmarked TR4.
  • the HA-TR4 binding was clearly specific because it was competed effectively by unlabeled DR1-HRE but not by a mutated oligonucleotide (Fig. 4).
  • the anti-hemagglutinin-specific monoclonal antibody was able to cause a supershift of the TR4-HA band, whereas it had no influence on the pattern of the HA- ⁇ TR4.
  • HA-TR4 and HA- ⁇ TR4 retroviruses were used to infect bone marrow cells as described above. HA-TR4 behaved identically to unmodified TR4, so that myeloid cells grew without problems were obtained. Surprisingly, growth of myeloid cells was also observed in HA- ⁇ TR4, although the total number of cells was somewhat lower than in HA-TR4. As expected, the infected with a Neovirus control cells showed limited growth potential and completed the proliferation after 4 to 6 days • in the culture.
  • TR4 and, to a lesser extent, HA- ⁇ TR4 effectively support outgrowth of myeloid cells from bone marrow, which shows that the growth-promoting activity of TR4 is not lost through the deletion of its DNA-binding domain.
  • RXR and its DNA-binding variant ⁇ RXR only partially repeat the TR4 effects on bone marrow cells.
  • TR4 has a strong repressive effect on RXR-mediated transcriptions. Therefore, a ⁇ RXR that no longer has a DNA binding domain was introduced into bone marrow cells via a retrovirus in order to check whether a dominant interfering RXR would develop a phenotype similar to TR4.
  • a full strand RXR was used in a control culture. While the ⁇ RXR and RXR samples initially showed an outgrowth, these cells stopped proliferation on the 9th day in the culture and from then on the cell numbers remained constant or began to decrease. All of this data indicates that extended proliferation is only achieved by TR4 and TR4 variants, whereas RXR promotes the growth of myeloid cells.
  • ⁇ RXR showed a similar effect on bone marrow cells as full-length RXR, which shows that, as with TR4, RXR DNA binding is entirely unnecessary for this activity.
  • myeloid differentiation inducers such as 9-cis-retinoic acid or TFA were added, and the cells were then examined for morphological changes and their adhesion properties.
  • further cells were treated with the chicken myelomonocyte growth factor (cMGF), with which a growth-promoting but no differentiating activity was detected in previous experiments.
  • cMGF chicken myelomonocyte growth factor
  • TPA rapidly initiated adhesion of the entire cell population, with no apparent differences observed between RXR, ⁇ RXR, TR4 and ⁇ TR4 cells.
  • Different concentrations of TPA were added to the cells and the morphological changes taking place were observed under the microscope. After prolonged TPA treatment (3 days), some of the cells acquired a multicellular nucleus morphology.
  • TR4 and ⁇ TR4 cells have high levels of C / EBPß and the promyelocyte marker Mim-1.
  • the protein expression of the TR4 cells was analyzed.
  • both HA-TR4 and HA- ⁇ TR4 cells had an abundant protein with a molecular mass of 35 kDa. This band was also observed in RXR and ⁇ RXR cells, but to a much lesser extent than in the TR4 cells. The identity of this protein was then determined. For this purpose, this band was isolated from a gel and peptide sequencing was carried out. By analyzing different peptide sequences, the protein was identified as the myb-induced myeloid protein 1, called Mim-1.
  • a Western blot with an anti-Mim-1-specific antibody additionally confirmed the identity of this protein.
  • the 18 kDA band found in the Coomassie blue stained gels is most likely a Mim-1 degradation product because it could also be stained with anti-Mim-1 antibody.
  • Mim-1 occurs in cytoplasmic granules in the form of normal and deformed promyelocytes.
  • C / EBPß another protein which occurs to a large extent in myeloid progenitors and is required for effective Mim-1 expression
  • C / EBPß another protein which occurs to a large extent in myeloid progenitors and is required for effective Mim-1 expression
  • TR4 plays a role in the initiation of outgrowth of bound granulocyte progenitors or in the prevention of terminal differentiation of these cells.
  • TR4 occurs to a high degree in hematopoietic cells and tissues of vertebrate organisms, and particularly strongly in myeloid cells. Furthermore, the influence of TR4 on hematopoiesis was revealed by the ectopic expression of TR4 in bone marrow cells. It was found that TR4 leads to an effective outgrowth of promyelocytes and is thus involved in the proliferation and differentiation of myeloid progenitor cells. In addition, it was shown that TR4 as well as ⁇ TR4, which has been freed from its DNA-binding domain, have essentially the same biological activities. Obviously, the DNA binding activity of TR4 is not required for its activities in hamatopoetic cells.
  • TR4 occurs in different hematopoietic lineages, but an effective outgrowth after ectopic expression in bone marrow cells was only observed in the myeloid area. Interestingly, although erythroid cells showed striking TR4 expression in all analyzed species, no growth of erythroid progenitor cells was observed. Furthermore, it was found that TR4 in particular has a slight growth-promoting activity when incorporated into existing erythroid progenitors.
  • the transcriptional activity of TR4 as a repressor is caused by various mechanisms, including the composition of the target site. Accordingly, TR4-mediated repression at certain DNA elements requires an intact DNA binding domain, as was also shown here.
  • transcriptional repression could be carried out by sequestering cofactors (transrepression) which, for example, involve AF-2 connect, be mediated and the transrepression consequently be carried out both by TR4 and ⁇ TR4.
  • TR4 and ⁇ TR4 show similar biological activities in promoting promyelocyte proliferation in vivo.
  • NR are able to modulate target gene expression not only as DNA-bound factors, but also through mechanisms that do not require direct DNA interactions. In most cases, such DNA-independent activities of the NR are carried out via protein-rotein interactions. The most likely candidates for such a function are corepressors and coactivators known to interact with the AF-2 domain of NR. Such a DNA-independent mechanism of TR4 activity would correspond to the observations made, which demonstrate a similar activity of TR4 and ⁇ TR4 in promyelocyte proliferation. A candidate for this role is RIP-140, a proven co-activator that interacts with TR4.
  • transrepression has priority due to RIP-140 sequestration and has been observed, for example, in PPAR / RXR-controlled gene expression.
  • TR4 is present in the cell nucleus, whereas ⁇ TR4 is mostly in the cell nucleus, but also in the cytoplasm of TR4-transformed chicken embryo fibroblasts and myeloid cells.
  • TR4 putative nuclear localization signal from TR4 (like the corresponding nuclear localization signal in the DNA binding region of TR2) is removed in ⁇ TR4.
  • the reduced cell nucleus expression of ⁇ TR4 could well explain the somewhat reduced proliferation potential of the ⁇ TR4 cells compared to TR4 cells.
  • TR4 as a regulator of myeloid development is a goal of pharmacological research and thus opens up new possibilities for the treatment of myeloid leukemia.
  • Fig. 1 Ha atopoetic cells and tissues show TR4
  • RNA of various cell types and tissues from humans (A), mice (B) and chickens (C) was analyzed for TR4 expression by Northern blot. TR4-specific transcripts are marked (arrowhead and star). 28S ribosome RNA stained with methylene blue is shown to demonstrate the RNA load.
  • Erbls erythroblasts
  • DC dendritic cells (Dendritic Cells)
  • DCprog. DC progenitors (SC progenitors)
  • SCF and STED SCF or SCF / TGF ⁇ -dependent erythroblasts.
  • Fig. 2 TR4 promotes the proliferation of bone marrow cells in vitro.
  • HA-TR4 and HA- ⁇ TR4 cells effectively show TR4 proteins according to detection by Western blot and anti-hemagglutinin-specific antibody.
  • Fig. 3 DNA binding activity and transcriptional activity of HA-TR4 and HA- ⁇ TR4.
  • TR4 The DNA binding activity of TR4 proteins was analyzed by band shift assays using complete cell extracts from the stably transfected chicken embryo fibroblasts shown in Fig. 3B. A 32 P-labeled oligonucleotide containing a DRI motif was used for this.
  • the HA-TR4 extracts showed a predominant band (arrowhead in the left field, lanes 4 and 6) that was missing in the HA- ⁇ TR4 samples (lane 7). TR4 favored a slightly faster complex migration compared to HA-TR4 (lanes 8 and 11).
  • HA-TR4 and HA- ⁇ TR4 were analyzed for their transcriptional activity by means of transient co-transfection experiments in chicken embryo fibroblasts.
  • the luciferase reporter construct contains rat CRBPII-RXRE.
  • Luciferase activity was normalized by cotransfection of a ß-galactosidase reporter plasmid. As indicated, 9cRA was added to the solution at a final concentration of 10 "6 M (+).
  • Fig. 4 Differentiation of TR4 and RXR cells in response to various stimuli.
  • the differentiation of the HA-TR4, HA- ⁇ TR4, RXR and ⁇ RXR cells on the 12th day in the culture was triggered with 9cRA (lxlO "6 M) or by TPA treatment (1 ⁇ g / ml) for 48 h
  • the differentiated adherent cells were then stained with a histological dye (DiffQuik).
  • a histological dye DiffQuik
  • chicken myelomonocyte growth factor 40 ng / ml
  • the density of the adherent cells was determined using NIH imaging software and the values of the cells prepared with TPA were arbitrarily set to 100.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne l'utilisation de TR4, d'activateurs de TR4, d'inhibiteurs de TR4 et/ou de molécules associées au TR4 en diagnostic, prévention, suivi, thérapeutique et/ou post-traitement de maladies tumorales et/ou de maladies du sang.
PCT/EP2002/011484 2001-10-12 2002-10-14 Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies WO2003033529A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362891A AU2002362891A1 (en) 2001-10-12 2002-10-14 Tr4, tr4 activators, tr4 inhibitors or tr4-associated molecules for treating leukaemic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10150183.8 2001-10-12
DE10150183A DE10150183A1 (de) 2001-10-12 2001-10-12 Mittel zur Behandlung von leukämischen Erkrankungen

Publications (2)

Publication Number Publication Date
WO2003033529A2 true WO2003033529A2 (fr) 2003-04-24
WO2003033529A3 WO2003033529A3 (fr) 2003-11-20

Family

ID=7702165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011484 WO2003033529A2 (fr) 2001-10-12 2002-10-14 Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies

Country Status (3)

Country Link
AU (1) AU2002362891A1 (fr)
DE (1) DE10150183A1 (fr)
WO (1) WO2003033529A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2032146A2 (fr) * 2006-05-09 2009-03-11 University of Rochester Procédés et compositions liés à tr4

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199673A1 (fr) * 2018-04-09 2019-10-17 President And Fellows Of Harvard College Modulateurs de récepteurs nucléaires et leurs procédés d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135493A (ja) * 1997-07-17 1999-02-09 Sumitomo Pharmaceut Co Ltd 新規な抗エストロジェン遺伝子治療剤
WO2001035101A2 (fr) * 1999-11-12 2001-05-17 University Of Rochester Suppression mutuelle entre des recepteurs d'hormones sexuelles et d'autres recepteurs nucleaires

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016368A1 (fr) * 1999-09-01 2001-03-08 Bristol-Myers Squibb Company Systemes de transcription in vitro et ses utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135493A (ja) * 1997-07-17 1999-02-09 Sumitomo Pharmaceut Co Ltd 新規な抗エストロジェン遺伝子治療剤
WO2001035101A2 (fr) * 1999-11-12 2001-05-17 University Of Rochester Suppression mutuelle entre des recepteurs d'hormones sexuelles et d'autres recepteurs nucleaires

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARTUNEK PETR ET AL: "Retinoid X receptor and c-erbA/thyroid hormone receptor regulate erythroid cell growth and differentiation." MOLECULAR ENDOCRINOLOGY, Bd. 12, Nr. 9, 1998, Seiten 1269-1279, XP002235922 ISSN: 0888-8809 *
DATABASE WPI Section Ch, Week 200125 Derwent Publications Ltd., London, GB; Class B04, AN 2001-244411 XP002235924 & WO 01 16368 A (BRISTOL-MYERS SQUIBB CO), 8. März 2001 (2001-03-08) *
KORITSCHONER NICOLAS P ET AL: "The nuclear orphan receptor TR4 promotes proliferation of myeloid progenitor cells." CELL GROWTH & DIFFERENTIATION, Bd. 12, Nr. 11, November 2001 (2001-11), Seiten 563-572, XP002235923 ISSN: 1044-9523 *
NASON-BURCHENAL KATHRYN ET AL: "RXRa overexpression in NB4 promyelocytic leukemia cells is growth inhibitory and renders the transfectants more sensitive to retinoid induced differentiation." ANTICANCER RESEARCH, Bd. 17, Nr. 5C, 1997, Seite 3951 XP001146567 Seventh International Conference on Differentiation Therapy;Versailles, France; October 5-8, 1997 ISSN: 0250-7005 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 05, 31. Mai 1999 (1999-05-31) & JP 11 035493 A (SUMITOMO PHARMACEUT CO LTD), 9. Februar 1999 (1999-02-09) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2032146A2 (fr) * 2006-05-09 2009-03-11 University of Rochester Procédés et compositions liés à tr4
EP2032146A4 (fr) * 2006-05-09 2010-02-17 Univ Rochester Procédés et compositions liés à tr4

Also Published As

Publication number Publication date
AU2002362891A1 (en) 2003-04-28
DE10150183A1 (de) 2003-04-24
WO2003033529A3 (fr) 2003-11-20

Similar Documents

Publication Publication Date Title
DE69232986T2 (de) TGF-BETA TYP III REZEPTOR, DAFüR KODIERENDE CDNS UND DEREN VERWENDUNG
DE69535462T2 (de) Zusammensetzung und Verfahren zur Inhibition der Filamentbildung des Amyloid-Betaproteins und seiner Neutotoxizität
DE69433518T4 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
DE69633272T2 (de) Methoden zur Krebsbehandlung und -kontrolle
DE69229219T2 (de) Neuartige, physiologisch aktive substanz epimorphin, für sie kodierende gene und antikörper gegen epimorphin
EP1381629A2 (fr) RECEPTEUR DU DOMAINE DE LA EDb-FIBRONECTINE
WO2003033529A2 (fr) Utilisation de tr4, d'activateurs de tr4, d'inhibiteurs de tr4 ou de molecules associees au tr4 pour traiter des leucemies
DE69631041T2 (de) Promotor des utrophingens
DE69633172T2 (de) Ndf-peptide
EP1332218B1 (fr) Substances declenchant une differenciation
EP1023445B1 (fr) Facteur de croissance derive de la cadherine et son utilisation
DE10230631A1 (de) Verwendungen von an Ngal bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen
DE10351627B4 (de) Modulation der Angiogenese durch Bartonella henselae
DE10006887A1 (de) Verbindungen, die die Aktivität oder die Konzentration des Regulatorproteins RS1 verändern
WO2000017232A2 (fr) Proteine regulatrice issue de keratinocytes humains
EP1248835A2 (fr) Fibroblaste genetiquement modifie
DE19856301C1 (de) Regulatorisches Protein pKe#83 aus humanen Keratinozyten
DE69230943T2 (de) Zellzyklus- Kontrollzusammensetzungen und Methoden diese zu benutzen.
DE60038531T2 (de) Transporter organischer anionen der plazenta und dessen gen
EP1004668B1 (fr) Protéine régulatrice pKe 83 de keratinocytes humains
DE69813677T2 (de) Humäne Serumglucocorticoidregulierte Kinase, ein Ziel für chronischer Nierenerkrankung und diabetische Nephropathie
EP1220920A1 (fr) Gene prv-1 et son utilisation
EP1072681B1 (fr) Protéine regulatrice pKe#165 des kératinocytes humaines
DE10054878A1 (de) Natriumkanäle vom Typus der peripheren Nerven
DE10234901A1 (de) Verwendung von am Mrp4 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP